VPIM
MREO

Vanguard Personalized Indexing Management’s Mereo BioPharma MREO Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,498
Closed -$15K – 1305
2022
Q1 		$15K Buy
+13,498
New +$17.5K ﹤0.01% 1202

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Personalized Indexing Management's MREO Position: Q2 2022 in Review

Vanguard Personalized Indexing Management sold out of Mereo BioPharma (MREO) in Q2 2022, closing a stake of 13,498 shares — an estimated $15K sold.

Vanguard Personalized Indexing Management first reported a position in MREO in Q1 2022 and held it in 1 quarter. The position peaked at $15K in Q1 2022. 64 funds tracked by Wall St. Rank hold MREO as of Q2 2022.

  • Vanguard Personalized Indexing Management reported no remaining Mereo BioPharma position as of Q2 2022 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 13,498 Mereo BioPharma shares in Q2 2022, an estimated $15K.
  • Vanguard Personalized Indexing Management first reported a position in Mereo BioPharma in Q1 2022 and held it in 1 quarter.
  • Vanguard Personalized Indexing Management's Mereo BioPharma position peaked at $15K in Q1 2022.
  • 64 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2022.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2022, filed 9 Aug 2022.